We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Oncternal Therapeutics Inc | NASDAQ:ONCT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.1502 | -1.81% | 8.16 | 8.13 | 8.50 | 8.16 | 8.16 | 8.16 | 143 | 15:23:07 |
```
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported) August 30, 2022
Oncternal Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
000-50549 |
|
62-1715807 |
(State or Other Jurisdiction |
|
(Commission File |
|
(IRS Employer Identification No.) |
12230 El Camino Real Suite 230 (858) 434-1113 |
|
|
(Address and zip code; telephone number, including area code, of registrant’s principal executive offices)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
ONCT |
|
The Nasdaq Stock Market, LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events
On August 30, 2022, Oncternal Therapeutics, Inc. submitted an Investigational New Drug Application (“IND”) for ONCT-808, its autologous chimeric antigen receptor T cell (CAR-T) targeting Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). The IND must be accepted by the U.S. Food and Drug Administration prior to commencing a clinical study of ONCT-808.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Oncternal Therapeutics, Inc. |
||
|
|
||
Date: August 31, 2022 |
By: |
/s/ James B. Breitmeyer |
|
|
|
Name: James B. Breitmeyer |
|
|
|
Title: Chief Executive Officer |
2
1 Year Oncternal Therapeutics Chart |
1 Month Oncternal Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions